Munich, Germany – August 28, 2025— CPTx, a pioneer in the development and manufacturing of novel genetic medicines built with single-stranded DNA (ssDNA), has announced the appointment of David Maier to lead the contract development and manufacturing (CDMO) business unit focused on ssDNA supply called gxstrands. Maier will build strategic partnerships and expand capacity and service breadth to meet growing demand for custom ssDNA manufacturing solutions enabling next-generation genetic medicines.
“Our unique fermentation-based upstream and precision downstream purification process deliver high-fidelity ssDNA with customizable lengths and diverse topologies at scalable yields,” said David Maier, President of gxstrands. “We are building a best-in-class CDMO partner for the future of gene and cell therapy and other genetic medicines applications, and I am excited to help grow this business globally.”
“Over the past decade, our team has developed and refined scalable ssDNA manufacturing processes,” said Hendrik Dietz, PhD, founder of CPTx. “We are excited to have David leading gxstrands, which now leverages this foundation to deliver high-fidelity, configurable ssDNA to customers worldwide. CPTx will remain focused on advancing novel ssDNA-powered in vivo gene therapies through both our internal in vivo CAR-T pipeline and collaborations with external partners.”
The lead in vivo CAR-T therapy program at CPTx leverages immune-silent ssDNA and lipid nanoparticle (LNP) delivery to enable repeat dosing and controllable, durable activity, which is difficult to achieve with viral vectors or mRNA. With CPTx focused on clinical development progress, the gxstrands business will evolve to supply critical ssDNA for CPTx therapeutic pipeline programs and for the global biopharmaceutical industry.
Mr. Maier comes to gxstrands with more than 20 years of biopharmaceutical executive and commercial experience. He has led a global business unit at West Pharmaceutical Services, developed new biologics CDMO offerings at Lonza, and held various leadership, transactional, and strategic positions at Novartis. He began his career as an officer in the U.S. Marine Corps and in management consulting at L.E.K. Mr. Maier has an MBA from Cornell’s Johnson School and a bachelor’s degree from Harvard University.
About CPTx
CPTx is redefining the future of genetic medicine through a single-stranded DNA (ssDNA) platform that enables safer, redosable, and scalable gene therapies.
CPTx’s lead proprietary development program is a new kind of in vivo CAR T-cell therapy using immune-silent single-stranded DNA delivered with LNPs, enabling repeat dosing, and controllable, long-lasting effects, something not possible with viral vectors or mRNA.
Learn more at cptx.bio or contact info@cptx.bio.
About gxstrands
gxstrands is the premiere single-stranded DNA (ssDNA) manufacturer. The company was originally built to meet the demands of therapeutic development at CPTx and has since evolved into a CDMO for pharma companies who recognize ssDNA as a critical enabler for gene and cell therapy programs. The platform provides high-quality knock-in templates for gene editing applications, including allogeneic CAR-T and stem cell editing.
Learn more at gxstrands.com or contact info@gxstrands.com.
Contacts:
CPTx investors
McDavid Stilwell
CFO
mcdavid.stilwell@cptx.bio
gxstrands investors
David.maier@gxstrands.com
Media
Beth Willers
White Matter Communications
bethw@whitemattercomm.com